Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Pfizer Inc.NYSE: PFE

Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other current liabilities falls 2.8% from a year ago

Other current liabilities stood at $22.81B at the end of Q2 FY2026, down 2.8% from a year earlier and up 17.2% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.

Context

  • Other current liabilities amounted to 11.3% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Other current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -2.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$22.81B+17.2% QoQ
Last fiscal yearDec 2025
$18.32B-21.0% YoY
Year agoJun 2025
$23.47B-2.8% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.8%——
1 year-21.0%——
3-year CAGR-11.0%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
18.32B USD
Year-over-year change
-21.0%
4-year CAGR
-10.3%

Other Current Liabilities vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -2.8% is the 3rd highest of 10, against a peer median of -41.1%.
  • Other current liabilities amounts to 11.3% of total assets for PFE, versus a peer median of 5.7%.
PFE Competitors
Other Current Liabilities for PFE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PFEPfizer Inc.Jun 2026$22.81B USD-2.8%-11.0%11.3%
MRKMerck & Co., Inc.Jun 2026$18.95B USD——14.6%
NVSNovartis AGJun 2026$15.32B USD-3.1%+4.6%12.6%
BMYBristol-Myers Squibb CompanyJun 2026$13.47B USD-6.7%+6.9%15.4%
LLYEli Lilly and CompanyJun 2026$11.66B USD+82.7%+93.3%8.2%
GILDGilead Sciences, Inc.Jun 2026$3.7B USD+3.2%+2.2%7.5%
GSKGSK plcJun 2026£2.36B GBP-41.1%-43.9%3.9%
AZNAstraZeneca PLCSep 2026$678.8M USD-42.3%-64.2%0.6%
SNYSanofiJun 2026€197M EUR-98.6%+7.4%0.2%
ABBVAbbVie Inc.Jun 2026$128M USD-69.0%+7.0%0.1%
JNJJohnson & JohnsonSep 2026$0 USD-100.0%-11.9%0.0%
Peer median (excluding PFE) —-41.1%+4.6%5.7%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.94B416M2.85B1.04B1.14B
Short-term Investments29.13B22.32B9.84B19.43B12.45B
Net Receivables15.75B14.53B15.54B14.78B15.84B
Inventory9.06B8.98B10.19B10.85B10.65B
Other Current Assets3.82B5.02B4.91B4.25B2.81B
Total Current Assets59.69B51.26B43.33B50.36B42.9B
Property, Plant & Equipment (Net)14.88B16.27B18.94B18.39B21.53B
Goodwill49.21B51.38B67.78B68.53B71.26B
Intangible Assets25.15B43.37B64.9B55.41B53.73B
Long-term Investments21.53B15.07B15.37B2.23B1.74B
Tax Assets3.34B6.69B3.71B8.66B9.7B
Other Non-current Assets7.68B13.16B12.47B9.82B7.3B
Total Non-current Assets121.78B145.94B183.17B163.04B165.26B
Total Assets181.48B197.21B226.5B213.4B208.16B
Account Payables5.58B6.81B6.71B5.63B5.24B
Short-term Debt2.24B2.93B10.35B6.95B3.48B
Tax Payables1.27B1.59B2.35B00
Deferred Revenue3.07B2.52B2.7B1.51B784M
Other Current Liabilities28.27B25.99B23.32B23.2B18.32B
Total Current Liabilities42.67B42.14B47.79B43B36.98B
Long-term Debt34.76B31.93B60.5B57.41B61.64B
Deferred Tax Liabilities349M1.02B640M2.12B2.4B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities26.24B26.2B28.28B20.09B18.07B
Total Non-current Liabilities61.34B59.15B89.42B81.9B84.4B
Total Liabilities104.01B101.29B137.21B124.9B121.39B
Common Stock473M476M478M480M481M
Retained Earnings103.39B125.66B118.35B116.73B114.61B
Accumulated OCI(5.9B)(8.3B)(7.96B)(7.84B)(8.07B)
Other Stockholders Equity00000
Minority Interest262M256M274M294M299M
Total Equity77.46B95.92B89.29B88.5B86.78B
Total Debt37B34.86B70.85B66.99B67.42B
Net Debt35.05B34.44B67.99B65.95B66.27B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.